research Baseline methotrexate does not impact the incidence of infliximab infusion reactions: Results from a Canadian real-world treatment registry
Clofazimine effectively treated ashy dermatosis in a patient.
Search
for
Sort by
Research
30-60 / 1000+ results research Adjuvant eflornithine to maintain IPL ‐induced hair reduction in women with facial hirsutism: a randomized controlled trial
Topical eflornithine helps maintain hair reduction after IPL therapy in women with facial hirsutism.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?
Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.
research Imiquimod-induced effluvium after intravaginal application for treatment of cervical intraepithelial neoplasia
Imiquimod used intravaginally for cervical issues can cause temporary hair loss, especially if severe side effects occur.
research Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
research Immunomodulators in the treatment of cutaneous lymphoma
Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.
research Effect of thalidomide combined with CHOP on patients with peripheral T-cell lymphoma
Thalidomide with CHOP is more effective for peripheral T-cell lymphoma than CHOP alone.
research Clinical efficacy and safety of low‐dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism
Low-dose flutamide helps reduce excessive hair growth and is even more effective with birth control, without bad effects on blood fats.
research Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome
Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
research Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 is generally safe for treating alopecia areata.
research 0282 Effect of systemic immunomodulators on incidence of alopecia areata: A retrospective cohort study
Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
research 15460 Perifollicular pink halo: A potential dermoscopic marker of inflammation in central centrifugal cicatricial alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research Alopecia secondary to severe discoid lupus responding to anifrolumab
Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
research Minoxidil
research Minoxidil
research Immunosuppressive treatment for proliferative lupus nephritis
Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.
research Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.
Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.
research Low-Dose Flutamide (125 mg/Day) as Maintenance Therapy in the Treatment of Hirsutism
Low-dose flutamide effectively maintains reduced hirsutism with no side effects.
research Hair Loss Associated with Teriflunomide Treatment
Teriflunomide can cause hair thinning.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research 1409 Temporary cell cycle arrest by ALRN-6924: A novel, p53-targeting strategy to protect human scalp hair follicles against cyclophosphamide-induced alopecia
ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
research Cemiplimab-Induced Alopecia Areata
A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
research 5α-Reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives
Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
research Hydrochlorothiazide/indometacin
A woman developed lupus after taking hydroxyurea for two years.
research Treatment of hirsutism with the pure antiandrogen flutamide
Flutamide effectively reduced excessive hair growth and improved related symptoms in hirsutism patients without significant side effects.
research Ruxolitinib: A novel molecule in the management of dermatological disorders
Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
research Treatment of Del(5q) Myelodysplastic Syndrome with All-Trans-Retinoic Acid and Tocopherol-α.
The treatment was not recommended due to limited effectiveness and significant side effects.